In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 331 to 340 of 376

TitleTypeExpected publication date
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy ID6161Technology appraisal guidanceTBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753Technology appraisal guidanceTBC
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Highly specialised technologyTBC
Tolebrutinib for treating secondary progressive multiple sclerosis ID6351Technology appraisal guidanceTBC
Topical antimicrobial dressings for locally infected leg ulcers: Late stage assessmentHealth technology evaluationTBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All